Previous 10 | Next 10 |
Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced that it has exercised its option to license SPC-15, a prophylactic...
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a develo...
Silo Pharma (NASDAQ: SILO) , a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its filing of a provisional patent application titled ‘Methods and Combinations for ...
Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing nov...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, ...
All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental st...
Springfield, Oregon--(Newsfile Corp. - February 27, 2024) - Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo" or "the Company"), a leading global psychedelics wellness company, announces that the Letter of Intent (LOI) to acquire NUGL (Kaya Group in Jamaica) previously announced...
News, Short Squeeze, Breakout and More Instantly...
SILO Pharma Inc Company Name:
SILO Stock Symbol:
OTCMKTS Market:
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced positive data in the final validation report from the recent pharm...
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing...
SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing n...